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The /32 integrin lymphocyte function-associated antigen 1 (LFA-1) mediates activation- 
dependent adhesion of lymphocytes. To investigate whether lymphocyte-specific ele­
ments are essential for LFA-1 function, we expressed LFA-1 in the erythroleukemic cell 
line K562, which expresses only the integrin very late antigen 5. We observed that 
LFA-1-expressing K562 cannot bind to intercellular adhesion molecule 1-coated surfaces 
when stimulated by phorbol 12-myristate 13-acetate (PMA), whereas the LFA-1-activat­
ing antibody KIM185 markedly enhanced adhesion. Because the endogenously expressed 
/31 integrin very late antigen 5 is readily activated by PMA, we investigated the role of the 
cytoplasmic domain of distinct j3 subunits in regulating LFA-1 function. Transfection of 
chimeric LFA-1 receptors in K562 cells reveals that replacement of the /32 cytoplasmic tail 
with the Pi but not the /37 cytoplasmic tail completely restores PMA responsiveness of 
LFA-1, whereas a /32 cytoplasmic deletion mutant of LFA-1 is constitutively active. Both 
deletion of the j32 cytoplasmic tail or replacement by the J31 cytoplasmic tail alters the 
localization of LFA-1 into clusters, thereby regulating LFA-1 activation and LFA-1 - 
mediated adhesion to intercellular adhesion molecule 1. These data demonstrate that 
distinct signaling routes activate ft  and f t  integrins through the /3-chain and hint at the 
involvement of lymphocyte-specific signal transduction elements in f t  and f t  integrin 
activation that are absent in the nonlymphocytic cell line K562.
INTRODUCTION
The f t  integrin lymphocyte function-associated anti­
gen 1 (LFA-1;1 CDlla/CD18 or aL/32) is a lymphocyte- 
specific adhesion receptor that coordinates different 
adhesive and signaling interactions within the im­
mune system (Kurzinger et al., 1981; Martz, 1987; Ar- 
naout, 1990; Springer, 1990). LFA-1 mediates cell-cell 
adhesion upon binding to any one of its ligands, 
which are intercellular adhesion molecule (ICAM) 1 
(Marlin and Springer, 1987), ICAM-2  (Staunton et al.,
* Corresponding author: Department of Tumor Immunology, 
University Hospital Nijmegen St Radboud, Philips van Leyden- 
laan 25, 6525 EX Nijmegen, the Netherlands.
1 Abbreviations used: ICAM, intercellular adhesion molecule; 
LFA-1, lymphocyte function-associated antigen 1; mAb, mono­
clonal antibody; PMA, phorbol 12-myristate 13-acetate.
1989), and ICAM-3 (de Fougerolles and Springer, 
1992; Fawcett et al, 1992; Vazeux et ah, 1992; de Foug­
erolles et al, 1993). Integrins are heterodimeric trans­
membrane molecules composed of an a-chain that is 
noncovalently linked to a /3-chain. Various integrin 
subfamilies can be distinguished by differences in 
their /3-chains (Hynes, 1987).
Besides f t  integrins, lymphocytes also express /31 
and f t  integrins. Similar to the f t  integrins, a4f t  is 
only expressed on lymphocytes and mediates adhe­
sion to vascular cell adhesion molecule 1 , muscosal 
addressing cell adhesion molecule, ac4, or the extracel­
lular matrix component fibronectin (Ruegg et aL, 1992; 
Altevogt et al., 1995; Berlin et al, 1995). In contrast, the 
ft integrins a4ft and a5ft are not lymphocyte-specific 
adhesion receptors, since they are found on a variety 
of other cell types (Hemler, 1988, 1990; Hemler et al,
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1990). a4px mediates adhesion to VCAM-1 , and the 
extracellular matrix component fibronectin, whereas 
a5f$v  predominantly binds to fibronectin (Hemler et 
al, 1987; Takada et al, 1987; Hemler et al, 1988; Al- 
tevogt et al, 1995).
LFA-1/ICAM- 1  adhesion requires activation of 
LFA-1  through intracellular signals (Martz, 1987; Dus­
tin and Springer, 1989; van Kooyk et al, 1989; Hynes, 
1992). This activation process, termed "inside-out" 
signaling, is common to all integrins including the /3: 
and p7 integrins (Keizer et al., 1988; Dustin and 
Springer, 1989; van Kooyk et al, 1989; Altieri, 1991; 
Dransfield et al, 1992b; Andrew et al, 1993; Landis et 
al, 1993). Activation of LFA-1 is thought to result in a 
conformational change in the a f p  heterodimer, lead­
ing to an enhanced binding affinity LFA-1 for its li­
gand ICAM-1 (Lollo et al, 1993). Both affinity (active 
conformation) and avidity (clustering) changes are re­
quired to obtain strong binding of LFA-1 to ICAM-1  
(Dustin, 1990). Affinity/avidity changes in LFA-1 de­
pend on an intact cytoskeleton, physiological temper­
ature, and binding of divalent cations, in particular 
Mg2* (Rothlein and Springer, 1986; Dransfield and 
Hogg, 1989; Figdor et al, 1990; Dransfield et al., 1992a). 
Binding of Ca to LFA-1 supports clustering (high- 
avidity state) of LFA-1 on the cell surface, resulting in 
enhanced LFA-1-mediated adhesion (Figdor et al, 
1990; van Kooyk et al, 1994).
Alternatively, binding of certain activating anti-in- 
tegrin antibodies/ or the divalent cation Mn , to the 
extracellular part of the integrin, can also induce an 
active conformation (high-affinity state) of the (ft, fi2, 
P7) integrin, resulting in increased adhesion to the 
ligand (Keizer et al, 1988; Robinson et al, 1992; An­
drew et al, 1993; Landis et al, 1993). It is thought that 
these activating anti-integrin monoclonal antibodies 
(mAbs) mimic ligand binding and stimulate postli­
gand binding signaling ("outside-in" signaling). Out- 
side-in signaling generates different intracellular sig­
nals, including phosphorylation of distinct tyrosine 
kinases and other proteins (Hynes, 1992; Kanner et al, 
1993; Arroyo et al, 1994).
Although the cytoplasmic tail of the a- and j3-chains 
of ft, filf and fi7 integrins are relatively short (46, 45, 
and 51 amino adds for the ft, ft, and p7 cytoplasmic 
tail, respectively) and do not contain any intrinsic 
kinase activity, the cytoplasmic tails seem to be in­
volved in transmitting inside-out signals as well as 
outside-in signals to and from the integrin molecule. It 
has been demonstrated that the adhesiveness of LFA-1 
is controlled by the cytoplasmic domain of the f t  
subunit, because truncation of the cytoplasmic f t  tail, 
but not the aL tail, eliminates LFA-1  binding to 
ICAM-1 (Hibbs et al, 1991b). In particular, mutations 
of a triplet of threonines (positions 758-760) and the 
phenylalanine residue at position 766, in the f t  cyto­
plasmic tail profoundly reduced the adhesiveness of
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LFA-1 (Hibbs et al, 1991a; Peter and O'Toole, 1995). It 
has been suggested that the altered adhesiveness due 
to mutation of the threonine triplet is caused by an 
altered cytoskeletal association/organization and not 
to an affinity change in LFA-1  (Peter and O'Toole, 
1995). Because deletion of the cytoplasmic domain of 
the aL subunit does not affect binding to ICAM-1 , it is 
hypothesized that the cytoplasmic tail of aL is pre­
dominantly involved in "postligand binding" events 
of this integrin (Hibbs et al, 1991b).
Similarly, truncation of the cytoplasmic domain of 
the ft integrin subunit impairs adhesion to both fi­
bronectin and laminin and has been shown to be im­
portant for cell spreading and localization to focal 
contacts (Solowska et al, 1989; Hayashi et al, 1990; 
Marcantonio et al, 1990; Reszka et al, 1992). Moreover, 
also partial removal of the p7 cytoplasmic domain 
displayed no ligand binding activity of a4ft  (Crowe et 
al, 1994).
In this study, we investigated whether a lympho­
cytic environment is required to mediate adhesion 
through the f t  integrin LFA-1 and whether this de­
pends on the cytoplasmic tail of the /3-chain. There­
fore, we used the erythroleukemic K562 cells to ex­
press either wild-type LFA-1, LFA-1 in which the 
entire cytoplasmic tail of the p2 was deleted (A724), or 
LFA-1 in which the cytoplasmic domain of the p2 was 
exchanged for the cytoplasmic domains of ft or P7. 
We demonstrate that the cytoplasmic tail of the 
/3-chain of integrins plays a pivotal role in regulating 
ligand binding affinity (active conformation) and avid­
ity (clustering) and suggest that K562 and lympho­
cytes use different signaling elements to activate inte­
grins.
MATERIALS AND METHODS
mAbs
mAbs SPV-L7 (IgGl), NKI-L15 (IgG2a), and NKI-L16 (IgG2a) reac­
tive with the a-chain of LFA-1 were raised as described previously 
(Keizer et al, 1985, 1988). The nonblocking mAb TS2/4 (IgGl) 
reactive with atL was provided by Dr. E Martz (Sanchez Madrid et 
al, 1982). mAb 60.3 (IgGl)/ directed against & was obtained from 
Dr. J.M. Harlan (Beatty et al, 1983). The anti-/32 mAb KIM 185 (IgGl) 
was used to activate integrins (Andrew et a l, 1993) and the 
anti-ft mAb TS2/16 to activate ft integrins (Hemler et a l,  1984; van 
de Wiel-van Kemenade et al, 1992). The anti-a5 mAb SAM-1 (IgGl) 
was used to block very late antigen 5-dependent adhesion (Keizer et 
a l , 1987).
DNA Constructs
The 4.2-kb a-chain of LFA-1 was cloned in the Xbal site of the 
pCDM8 vector that directs expression of from the cytomegalo­
virus (CMV) ADI69 immediate early promotor (pCDLl). The 3' end 
of /32 was cloned as an EcoRI-Bgffl fragment in the pRc/CMV vector 
(containing a neomycin resistance gene; Invitrogen, San Diego, CA). 
Within this sequence is a unique Apal site at position 1980. The 
C-terminal end was rebuilt from this site with 10 overlapping oli­
gonucleotides and amplification by the polymerase chain reaction to 
obtain the appropriate hybrids. For the f e /f t  chimeric protein,
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amino acid 752 of ft  (cytoplasmic domain) was joined to amino acid 
723 of f t  and for the ft/0 7  chimeric protein, amino acid 747 of f t  
(cytoplasmic domain) was joined to amino acid 723 of ft. The 
deletion mutant of LFA-1 was made by truncation of the f t  cyto­
plasmic tail from amino acid 724 (see Figure 2).
Cell Culture and Transfection
Stable LFA-1-expressing K562 transfectants were established by 
electroporation of 107 cells in 0.8 ml of phosphate-buffered saline at 
280 V and 960 /aF with the aL (in pCDM8) and the wild-type f t  
subunit (in pRc/CMV), the aL and f t  cytoplasmic truncated subunit 
(A724), or the aL and the chimeric f t / f t -  or ft/ft-chain  of LFA-1. 
K562-LFA-1 transfectants were cultured in RPMI1640 medium (Life 
Technologies, Paisley, Scotland), supplemented with 10% fetal calf 
serum (BioWhittaker, Venders, Belgium), and 1% antibio tics/anti- 
mycotics (Life Technologies). After 48 h the neomycin analogue, 
Geneticin (2 mg/ml, Life Technologies) was added to the culture 
medium. The different transfectants were sorted three times to 
obtain a homogenous population of cells expressing high levels of 
LFA-1. Positive cells were stained directly with fluorescein isothio- 
cyanate (FITC)-labeled TS2/4 mAb, Cells were sorted with the 
Coulter Epics Elite (Coulter, Hialeah, FL).
Immunofluorescence Analysis
Expression of LFA-1 on the transfectants was determined by immu­
nofluorescence. Cells (2 x  105 cells) were incubated (30 min, 4°C) in 
phosphate-buffered saline, containing 0.5% (wt/vol) bovine serum 
albumin (BSA, Boehringer Mannheim, Mannheim, Germany) and 
0.01% sodium azide (10 mM, Merck, Hohenbrunn, Germany), with 
appropriate dilutions of either an anti-integrin mAb or an isotype- 
matched control antibody, followed by incubation with FITC-la- 
beled goat (Fab')2 anti-mouse IgG mAb (Zymed Laboratories, San 
Francisco, CA) for 30 min at 4°C. The relative fluorescence intensity 
was measured by FACScan analysis (Becton Dickinson, Oxnard, 
CA).
Adhesion Assay
Binding of LFA-1-positive cells to ICAM-1 was performed with 
ICAM-1 fusion proteins consisting of the five Ig-like domains of 
ICAM-1 fused to a human IgGl Fc fragment (ICAM-1 Fc). ICAM-1 Fc 
was generated by transfecting mouse L cells with the vector 
pICAM-1-IgGl by calcium phosphate precipitation (calcium phos­
phate transfection system, Life Technologies) using a standard pro­
tocol (Fawcett et aL, 1992). Culture supernatant was purified by 
protein A chromatography and eluted by 3.5 M MgCl2 and 10% 
glycerol.
Ninety-six-well flat-bottomed plates (MaxiSorp, Nunc, Roskilde, 
Denmark) precoated with 50 ¿il of goat anti-human Fc-spedfic 
F(ab')2 (4 ¿Lg/ml; Jackson ImmunoResearch Laboratories, West- 
grove, PA) for 1 h 37°C and blocked with 1 % BSA in TSM (20 mM 
Tris-HCl, pH 8,150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2) for 30 min 
at 37°C were coated with 0.2 /ig/m l ICAM-lFc protein overnight at 
4°C. Stably transfected CDlla/CD18 K562 cells were labeled with 
Na2slCr04 (Amersham International, Buckinghamshire, England) 
for 45 min at 37°C. Radiolabeled cells were washed and preincu­
bated for 15 min at room temperature with different stimuli 150 nM 
phorbol 12-myristate 13-acetate (PMA, Calbiochem, La Jolla, CA), 5 
/xg/ml KIM185, or 5 /xg/ml TS2/161 and/or blocking mAbs (10 
jig/ml). Cells were allowed to adhere for 45 to 60 min at 37°C. 
Unbound cells were removed by washing with TSM supplemented 
with 0.5% (wt/vol) BSA. The adherent cells were lysed with 100 jil 
of 2% Triton X-100 and radioactivity was quantified in a gamma 
counter. Results are expressed as the mean percentage of cells 
binding from triplicate wells. Values are depicted as inte- 
grin-specific adhesion: percentage of cells binding -  percentage of
cells binding in the presence of an integrin-blocking mAb (NKI-L15 
or SAM-1).
Radiolabeling and Immunoprécipitation
Transfectants were surface labeled with Na12SI (Amersham Interna­
tional). For immunoprécipitation, 107 cells were solubilized for 1 h 
at 4°C in immunoprécipitation buffer (IPB), which contained 1% 
Nonidet P-40 (Sigma, St. Louis, MO), 50 mM triethanolamine (pH 
7.8, Sigma), 150 mM NaCl, 1 mM CaCI2, 2 mM MgCl2/ and as 
protease inhibitors (Sigma) 1 mM phenylmethylsulfonyl fluoride, 
0.02 mg/ml ovomucoid trypsin inhibitor, 0.02 m g/m l leupeptin, 
and 1 mM Na-P-tosyl-L-lysine chloromethyl ketone were added. 
Nuclear debris was removed from the lysates by centrifugation at 
13,000 X g for 15 min at 4°C Lysates were precleared by successive 
incubation with mouse IgG covalently coupled to protein A-Sepha- 
rose CL-4B beads (Pharmacia, Piscataway, NJ). Precleared ceU ly­
sates were immunopredpitated with specific mAb, directed against 
either LFA-1 or VLA-5, coupled to protein A-Sepharose CL-4B for 1 
to 2 h at 4°C. The immunoprecipitates were removed from the 
lysates by centrifugation at 13,000 x  g .  Subsequently, immunopre­
cipitates were washed extensively in IPB and analyzed under re­
ducing conditions with 5% 0-mercaptoethanol in SDS sample 
buffer. SDS-PAGE was carried out on vertical slab gels (5-15%) 
according to a modification of the Laemmli procedure (Laemmli, 
1970). Kodak XAR film was used in combination with intensifier 
screens (Cronex Lightning Plus; DuPont, Newton, CT) for autora­
diography of t2SI-labeled materials.
Confocal Microscopy
Cells were fixed with 0.5% paraformaldehyde. Fixed cells were 
stained with TS2/4 mAb (10 ¿¿.g/ml) for 30 min at 37°C followed by 
incubation with FITC-Iabeled goat (Fab')2 anti-mouse IgG mAb 
(Zymed Laboratories) 30 min at room temperature. Cells were at­
tached to poly-L-lysine-coated glass slides, after which cell surface 
distribution of integrins was determined by confocal laser scanning 
microscopy (CLSM) at 488 nm with a krypton/argon laser (Bio-Rad 
1000, Hercules, CA). The CLSM settings were: lens, 60X; gain, 1300; 
pinhole, 1.5 #xm; and magnification, 1.5 X, The same instrument 
settings of the CLSM were used throughout the distinct experi­
ments.
RESULTS
Expression and Function of Wild-Type LFA-1 in the 
Erythroleukemic K562 Cells
LFA-1  (aL/32) is an adhesion receptor that is exclu­
sively expressed on lymphocytes. To investigate the 
importance of a lymphocytic environment for the ad­
hesive function of LFA-1, we transfected both wild- 
type aL- and j32-chain cDNA in erythroleukemic K562 
cells that do not express the lymphocyte-specific fi2 
and /37 integrins endogenously. The transfectants ex­
press high levels of the heterodimer LFA-1 on their 
cell surface as detected by staining of the cells with 
mAb directed against either aL (SPV-L7) or /32 (60.3; 
see Figure 3A).
The capacity of LFA-1 on K562 cells to bind its 
ligand ICAM-1 was determined after activation of 
LFA-1 with PMA or the activating anti-/32 mAb 
(KIM185) and was compared with the adhesion capac­
ity of VLA-5, the only endogenously expressed Pi 
integrin. Figure 1A demonstrates that the LFA-1 -trans-
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Figure 1. Capacity of K562 a Lfa  transfectants to bind to ICAM-1 or 
fibronectin. K562-aLfa ce^  were preincubated in medium (control), 
PMA (50 nM), the activating anti-fa mAb KJM185, or the activating 
anti-ft mAb TS2/16 (5 /xg/ml). Depicted is the mean percentage of 
either LFA-1-specific adhesion to ICAM-1 or VLA-5-specific adhe­
sion to fibronectin. Integrin-specific adhesion: percentage of cells 
binding -  percentage of cells binding in the presence of an integrin 
blocking mAb (NKI-L15 or SAM-1). Data are representative of four 
experiments.
fected K562 cells express functional LFA-1 molecules 
because KIM185 readily induces LFA-1 -mediated 
ICAM-1 binding. Surprisingly, PMA was not able to 
induce LFA-1 -mediated adhesion to ICAM-1. This is 
not due to a general nonresponsiveness of K562 cells 
to PMA because it significantly enhances VLA-5-me- 
diated binding to fibronectin. Similar to KIM185, the 
activating anti-ft mAb TS2/16 effectively stimulated 
VLA-5-mediated adhesion (Figure IB).
The observation that PMA could enhance ft inte­
grin (VLA-5)-mediated adhesion but not f t  integrin- 
(LFA-1) mediated adhesion suggests that distinct sig­
naling elements are involved in the PMA-induced f t  
and ft integrin activation.
Expression of p 2-Chimeric LFA-1 Molecules in 
Erythroleukemic K562 Cells
To determine whether the observed differences be­
tween PMA responsiveness of ft and f t  integrins are 
due to differences in the cytoplasmic tail, we gener­
ated LFA-1 molecules in which the cytoplasmic tail of 
the ft-chain was truncated close to the transmem­
brane region at amino add position 724 (K562-aLf t /  
A724) or replaced with that of the ft-chain or the 
/37-chain (K562-aLf t / f t  and K562-aLf t / f t ,  re spec-
tively). Figure 2 shows the amino acid sequence of the 
different LFA-1 chimeras. Asterisks mark the amino 
acid sequence homology of the cytoplasmic domain of 
the three distinct /3-chains. Both ft  and f t  integrins are 
predominantly expressed by lymphocytes, whereas ft  
integrins are widely distributed.
The chimeric ft-chains: /32//31/ f t / f t  a^d /32/A724 
were transfected along with the wild-type a-chain (aL) 
in K562. All transfectants expressed equally high lev­
els of LFA-1  (Figure 3A). Our unpublished observa­
tions demonstrated that LFA-1 was expressed as a 
heterodimer on the cell surface, since all transfectants 
expressed equally high levels of the MHM23 epitope 
that has been reported to detect an a //3-association- 
dependent epitope on LFA-1 (Hildreth and August, 
1985). These data demonstrate that deletion of the p2 
cytoplasmic tail or replacement of the /32 cytoplasmic 
tail for the ft or f t  cytoplasmic tail does not alter the 
overall conformation of the LFA-1 a / p  heterodimer. 
All transfectants show similar levels of the endog­
enously expressed ft integrin, VLA-5 (Figure 3A).
To verify that the chimeric LFA-1 molecules 
aLf t / f t  and aLft//37 did not associate with endoge­
nous a5-chain in K562, LFA-1 and VLA-5 were immu- 
noprecipitated from all transfectants. f t  wild-type, 
chimeric ft-chains, and aLft/A724 associated with ocL 
and not with as (Figure 3B, lanes C, D, F, G, I, J, L, and 
M, observed as the thick bands of 185 and 95 kDa). 
Similarly, immunoprécipitation with an anti-a5 mAb 
showed that VLA-5 does not associate with aL or /32 
(Figure 3B, lanes A, E, H, and K, observed as one thick 
band of 130-135 kDa, because, under reduced condi­
tions, the oi5- and ft-chains have approximately the 
same molecular weight).
Cytoplasmic f t  Domain Restores PMA 
Responsiveness of LFA-1 in K562 Cells
Next, we investigated the capacity of the cytoplasmic 
tail of the ft or f t  integrin to restore activation of 
LFA-1 by PMA. Wild-type LFA-1 (Figure 4) and the 
chimeric LFA-1 transfectants aLf t / ft  and a L/32//37 
showed increased binding when activated by the LFA- 
1 -activating antibody K3M185. The cytoplasmic tail of 
f t  in the aLf t / f t  transfectant did not restore PMA-
am inoacid
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*
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I N P R 0 Q E A D S P T L
Figure 2. Comparison of amino acid se­
quence of the fa, fa, and fa  cytoplasmic do­
main. The amino acids sequence is depicted 
in the single-letter code. One amino add gap 
was inserted into the 02-chain for alignment 
with the other /3-chains. Asterisks mark the 
homology in amino add sequences between 
either the fa  and fa or the fa and fa cyto­
plasmic domain. The boxes indicate amino 
acid sequences implicated in integrin function and activation. Between brackets is depicted the amino add position of fa, at which the 
cytoplasmic domain of the fa  & deleted or the first amino acid sequence of the corresponding fa or fa  cytoplasmic domain is joined to the 
transmembrane part of fa, creating the distinct chimeric LFA-1 transfectants (Erie el at., 1991).
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Figure 3. Expression and immunoprecipitation of LFA-1 and VLA-5 on the chimeric LFA-1 transfectants. (A) K562-a( 02/ K562-fft j32//3-„ 
K562-aL02/ 0 7, and a L02/A724 transfectants were stained with iso type-matched control antibodies or specific antibodies directed against the 
a subunit (SFV-L7) or the 0 subunit (60.3) of LFA-1 or against VLA-5 (SAM-1). (B) K562-a J32 transfectants (lanes A-D), K562-«t 0 2/A724 
(lanes E-G), K562-aL02/ 07 (lanes H and J), and K562-aL0 2/ 0 |  (lanes K-M) were immunoprecipitated with the anti-VLA-5 mAb SAM-1 (lanes 
A, E, H, and K), the anti-LFA -la mAb (SPV-L7) (lanes C, F, I, and L), or the an tv LFA-10 mAb 60.3 (lanes D, G, j, and M). As a control for 
specifically precipitated proteins, lysates were also precipitated with normal mouse serum (lane B).
induced binding to ICAM-1. In contrast, the cytoplas­
mic tail of fi] in the chimeric otLp2/ p -1 transfect ant 
restored PM A responsiveness, which is not dependent 
on expression levels of chimeric cxLp2/fiv  since our 
unpublished results have shown that transfectants ex­
pressing low levels of fi2/  f t  also respond to PM A. In 
addition, increasing the concentration of coated 
ICAM-lFc did not alter the PMA nonresponsiveness 
of wild-type LFA-1 in K562 (Figure 5A). Whereas 
PIviA stimulated binding of chimeric otLP2/P\ to 
ICAM-1 to an extent similar to the KIM 185~stimulated 
adhesion of these cells, both independent of the con­
centration of coated ICAM-lFc (Figure 5B). Similarly, 
also titration using higher doses of PMA did not alter 
the PMA nonresponsiveness of wild-type LFA-1 in 
K562 (Figure 5C), In contrast to both the chimeric and 
wild-type LFA-1 transfectants, the cxLfi2/&724 trans- 
fectant binds ICAM-1 equally well in the absence or 
presence of the activating mAb KIMI85 or PMA (Fig­
ure 4), Adhesion was LFA-1 mediated since antibodies 
directed against LFA-1 (Figure 4) or ICAM-1 inhibited 
the cell binding completely and mock transfectants 
always showed less than 2% adhesion to ICAM-1 as 
demonstrated by our unpublished results. These data 
indicate that the Pv  but not the fi7, cytoplasmic do­
main is capable of restoring PMA responsiveness of
LFA-1 in ¥362 and that the cytoplasmic tail of fi2 is 
important in regulating LFA-1 activation. The obser­
vation that PMA could still enhance p } integrin (VLA- 
5)-media ted adhesion to fibronectin of all transfectants 
(Figures 1 and 4) again suggests that distinct intracel­
lular routes are involved in fi2 and fi7 compared with 
fix integrin activation.
Clustering of LFA-1 on the Cell Surface Is Regulated 
by the fi~€hain
We determined whether truncation of the fi2 cytoplas­
mic domain or replacement of the fi2 cytoplasmic do­
main by the corresponding / 3 t  or f i 7  cytoplasmic do­
mains affected the distribution of cthfi2 irvtegrins at the 
cell surface. Altered distribution of integrins may af­
fect the avidity state of the receptors, facilitating li­
gand binding (Figdor et al„ 1990; van Kooyk et a l , 
1994; Lub et al. ,  1995). Therefore, wild-type (o:L/32)/ the 
deletion mutant (aLfi2/ A724), and the j32~chimeric 
LFA-1 transfectants (otLp2/P\ and « l ^ / ^ i )  were 
stained with the anti-LFA-1 antibody NKI-L16, which 
detects Ca2'^-dependent clustering of LFA-1 on the cell 
surface (Keizer et al., 1988; van Kooyk et al, 1994). 
Figure 6 demonstrates that wild-type LFA-1 transfec­
tants express low levels of the LI 6 epitope compared
Vol. 8, April 1997 723
M. Lub el a i
ICAM-l Fibronectin
Control PMA KIM 185
«LP2/P1
“ LP2/P7
«LP2/A
Control PMA TS2/16
Figure 4. Cytoplasmic domain restores 
PMA responsiveness of LFA-1 in K562 cells. 
K562-aLj32/|31 and K562-aLf32/  ft? transfectants 
and K562-aL^ 2/A724 were preincubated in me­
dium (control), PMA (50 nM), or with the acti­
vating anti-/32 mAb KIM185 (5 ¿¿g/ml) or acti­
vating anti-fr mAb TS2/16 (5 pig/ml) and 
allowed to adhere for 45-60 min at 37°C. Ad­
hesion was performed in the absence or pres­
ence of the LFA-1 blocking mAb (NKI-L15) or 
VLA-5 blocking mAb (Sam-1) to ICAM-l or 
fibronectin, respectively. Depicted is the mean 
percentage of LFA-1-specific binding to 
ICAM-l and VLA-5-specific adhesion to fi­
bronectin of three independent wells. Integrin- 
specific adhesion: Percentage of cells binding — 
percentage of cells binding in the presence of an 
integrin blocking mAb. Data are representative 
of three experiments.
with expression of a regular anti-LFA-1 (NKI-L16: 
SPV-L7 peak channel ratio is approximately 0.3). Sim­
ilarly, aL/32/  f t  transfectants show low LI 6 expression 
indicating that the cytoplasmic domain of f t  does not 
affect LFA-1 distribution (NKI-L16:SPV-L7 peak chan­
nel ratio is approximately 0.3). In marked contrast, 
aLf t / f t  and aLft/A724 transfectants show high ex­
pression of the LI 6 epitope, comparable to expression 
of the SPV-L7 epitope, indicating that all LFA-1 mol­
ecules express the LI6 epitope (NKI-L16:SPV-L7 peak 
channel ratio is roughly 1 ).
To determine whether deletion or replacement of 
the f t  cytoplasmic domain for the ft cytoplasmic 
domain directly affects the distribution of LFA-1 on 
the cell surface, CLSM studies were performed with 
all LFA-1 transfectants. Figure 7 demonstrates that 
LFA-1 is homogenously distributed on the cell surface 
of both wild-type (Figure 7A, only two of seven cells 
show some clustering of LFA-1) and chimeric « t f t / f t  
transfectants (Figure 7C), whereas on the cell surface 
of all chimeric aLf t / f t  (Figure 7B) and aL02/A724 
transfected cells (Figure 7D), LFA-1 is distributed in 
clusters. Clustering was not attributed to a higher 
expression level of LFA-1 (Figure 3A). These data 
indicate that either deletion or replacement of the f t  
cytoplasmic domain for the ft cytoplasmic domain 
dramatically affects the distribution of LFA-1, as well 
as results in an increment in the LI6 epitope expres­
sion. Moreover, our unpublished results demon­
strated that VLA-5 is similarly distributed into small 
clusters on all K562 transfectants. It should be noted 
that despite the strong clustering of aLf t / f t  receptors
on the cell surface stable binding to ICAM-l still de­
pends on activation of the receptor with PMA/ in 
contrast to the aLft/A724 transfectants that express 
constitutively active LFA-1 molecules.
DISCUSSION
Our results demonstrate that 1 ) PMA cannot activate 
LFA-1  when expressed in erythroleukemic K562 cells, 
despite the fact that PMA readily activates endog­
enously expressed ft integrins. 2) Expression of f t  
chimeric receptors in K562 reveals that the ft cyto­
plasmic tail but not the f t  cytoplasmic tail restores 
PMA responsiveness of LFA-1 . 3) Lymphocyte-spe- 
cific signal transduction elements may be involved in 
f t  and f t  integrin activation that are absent in K562 
cells. 4) Inside-out signaling (by PMA) is mediated by 
the ftchain of integrins. 5) Replacement of the f t  
cytoplasmic tail with that of ft alters the surface dis­
tribution of LFA-1 into clusters and facilitates ICAM-l 
binding. 6) Deletion of the entire f t  cytoplasmic do­
main localizes LFA-1  molecules into clusters and re­
sults in constitutively active receptors.
The PMA nonresponsiveness of LFA-1 in K562 cells 
is not restricted to this integrin only but holds also for 
the other two ft  integrins Mac-1 and p i50.95 (Ortlepp 
et aL, 1995) and is not dependent on the concentration 
of the ligand presented or on the concentration of the 
stimulus (Figure 5). Our finding that the cytoplasmic 
tail of the f t  integrin cannot revert the PMA nonre­
sponsiveness of LFA-1  in these cells predicts that 
transfection of f t  integrins into K562 (these cells do
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Figure 5. PMA nonresponsiveness of LFA-1 expressed in K562 is 
independent on the concentration ICAM-1 coated (A and B) or the 
amount of stimulus PMA to induce adhesion (C and D). K562-aL/32 
(A) and K562-« J32//3j (B) were preincubated in medium (W), PMA 
(50 nM, A), or with the activating anti-/32 mAh KIM185 (5 /xg/ml, #) 
and allowed to adhere to different concentrations of ICAM-1 Fc 
(500-25 ng/ml) for 45 to 60 min at 37°C in the absence or presence 
of the LFA-1-blocking mAb (NKI-L15). Similarly, K562-aL/3z (C) and 
K562-aL/32//31 (D) were stimulated with different concentrations of 
PMA (5-300 ng/ml, A). High amounts of PMA were still incapable 
of restoring the PMA nonresponsiveness of LFA-1, whereas the acti­
vating mAb KIM 185 enhanced adhesion (O). Depicted is the mean 
percentage of LFA-1-specific binding to ICAM-1 of three independent 
wells. LFA-1-specific adhesion: percentage of cells binding -  percent­
age of cells binding in the presence of a LFA-1-blocking mAb (NKI- 
L15). Data are representative of three experiments.
not endogenously express fa integrins), such as aAfa, 
will not allow the cells to respond to PMA. This sug­
gests that K562 cells lack intracellular signaling ele­
ments required to regulate adhesion through the lym­
phocyte-specific f t  and f t  integrins. The finding that 
the cytoplasmic tail of the f t  integrin completely re­
stores PMA responsiveness of LFA-1 in K562 cells 
cannot be attributed to a higher expression level of the 
fa /fa  chimeric receptors, since our unpublished re­
sults demonstrate that transfectants expressing low 
levels of f t / f t  also respond to PMA. Our finding that 
the f t  integrin VLA-5, which is endogenously ex­
pressed by the K562 cells, responds to PMA by allow­
ing the cells to bind its ligand fibronectin demon­
strates that the intracellular signaling elements 
activated by PMA are different for f t  integrins com­
pared with f t  and fa integrins.
Our results demonstrate that the cytoplasmic do­
main of the fa chain of integrins plays an important 
role in the inside-out signaling initiated by PMA. 
Whether PMA directly or indirectly activates fa hite- 
grins via its /3-chain requires further study. Previ-
Control
LFA-1 a  
NKI-L16
LFA-1 a  
SPV-L7
45
500
s0a
saÜ
10" 101 to" iow 10* 102 10 
fluorescence intensity
10* #
aLp2^
Figure 6. Expression of the LFA-1-clustering-dependent L16 
epitope. K562-aJ32, K562-aJ32//3j, K562-aJ32/  fi7/ and K562-a J32/  
A724 transfectants were stained with iso type-matched control anti­
bodies, the mAb NKI-L16, which reports LFA-1 clustering, or with 
a regular mAb directed against the a  subunit (SPV-L7) of LFA-1. 
Data are representative of five experiments.
ously, it has been shown that PMA leads to phosphor­
ylation of the serine residue at position 756 in the f t  
cytoplasmic domain (Hibbs et ah, 1991a). However, 
mutation of this serine residue does not impair 
ICAM-1 binding, demonstrating that phosphorylation 
at this position is not crucial for adhesion to ICAM-1 
(Hibbs et ah, 1991a). Alignment of the fa and f t  cyto­
plasmic domains to the f t  cytoplasmic domain re­
vealed that the serine residue is conserved in both f t  
and f t  (Figure 2), indicating that this serine residue 
cannot explain the differences observed in the chi­
meric receptors expressed in K562. Mutations of a 
triplet of threonines (amino acids 758-760) and a phe­
nylalanine residue at position 766 in the f t  cytoplas­
mic domain have been shown to completely abrogate 
ICAM-1 adhesion. Interestingly, a similar triplet of 
threonines and phenylalanine residue are present in 
the f t  cytoplasmic domain and are absent in the fa 
cytoplasmic domain. Therefore, it is tempting to spec­
ulate that these residues may be important in the 
lymphocyte-specific signal transduction pathway 
(Hibbs et ah, 1991a). To determine the precise residues 
in the fa cytoplasmic domain involved in the PMA 
induced signaling, mutations studies should be per­
formed (work in progress).
Our LFA-1 deletion mutant K562-at ft/A724, which 
lacks the complete fa cytoplasmic tail (45 amino acids 
long), was found to be constitutively active in K562
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Figure 7. Surface distribution of LFA-1 as determined by CLSM. 
Cells were fixed (0.5% paraform aldehyde) and subsequently stained 
with the anti-LFA-1 mAb TS2/4 and goat anti-mouse (Fab'^-FITC 
second antibodies. The difference in colors depicts the intensity of 
expression of LFA-1 molecules on the cell surface from red to yellow 
to green equals low am ounts to high amounts. LFA-1 is localized in 
large clusters on .K562-aL/32/j3i (B) and  K562~aL/32/A724 (D), 
whereas LFA-1 is more hom ogenously expressed on K562~aLfi2 (A) 
and K562~aL02/07 transfectants (C). The instrument settings of the 
CLSM were the same for all micrographs: lens, 60X; gain, 1300; 
pinhole, 1.5 /im; magnification, 1 .5x . One of three experiments is 
shown.
cells. Similar observations were made when the com­
plete cytoplasmic tail of the p 7 was deleted (A747, 
deletion of 51 amino acids) in a 4p 7 (Crowe et a l , 1994) 
or when the com plete cytoplasmic tail of the p 3 was 
deleted (A744, deletion of 45 amino acids, the f t  cyto­
plasmic ta.il is 47 amino acids long) in a1Ibf t  (Hughes 
et a l , 1995). In contrast, w hen  the first 28 amino acids 
of the N-terminal region of the cytoplasmic tail of 0 2 
were deleted, no effect on ICAM-1 binding activity 
was observed (Hibbs et a l ,  1991a). Similarly, mutants 
containing deletion greater than 5-15 amino acids at 
the C-terminal end of the f t  cytoplasmic domain nei­
ther promoted adhesion nor localization of f t  inte­
grins in focal contacts (Solowska et a l ,  1989; Hayashi et 
al., 1990; Marcantonio et a i , 1990). In contrast, deletion  
of 39 amino acids C-terminal of the cytoplasmic tail 
(A759, f t  cytoplasmic tail is 46 amino acids long) 
impairs the binding capacity to both laminin and fi~ 
bronectin. Likewise, partial removal of the C-terminal 
part of the J37 cytoplasm ic dom ain (A773) of the a 4fi7 
integrin displayed no ligand binding activity to 
VC AM-1 (Hayashi et a l 1990; Crowe et ai., 1994). 
These distinct findings can be attributed to the sites
where the cytoplasmic tails of the ftchains were de­
leted. The different p  cytoplasmic tails share high ho­
m ology in their membrane-proximal region, especially 
the DRRE sequence is conserved between the different
p  cytoplasmic tails (Figure 3, D759RRE762 of ft). C om ­
parison of the positions at which the distinct p  cyto­
plasmic tail were truncated suggests that deletion of 
the conserved aspartic acid residue corresponding to 
position 731 in the p 2 tail results in a constitutively  
active molecule, indicating that this residue is most 
important in regulating integrin activation. In con­
trast, it seems that in deletion mutants in which this 
conserved aspartic acid residue is not rem oved, the 
integrin activity can still be regulated. Moreover, 
amino acid sequences more C-terminal of the p  cyto­
plasmic tail are more likely important in ligand bind­
ing capacity rather than in regulation of integrin acti­
vation (Solowska et a i ,  1989; Hayashi et a l ,  1990; 
Marcantonio et a l ,  1990; Hibbs et a l ,  1991a,b; Crowe et 
a l ,  1994; Hughes et a l ,  1995). The hypothesis that the 
conserved aspartic acid residue (Figure 3, D759 of f t )  is 
pivotal in the regulation of integrin activation, is also 
supported by our finding that the LFA-1 deletion m u ­
tant K562-aL/32/  A724, which lacks the entire cytoplas­
mic p 2 tail including the conserved DRRE sequence, 
has shown to be constitutively active.
The observation that f t /  f t  chimeric LFA-1 recep­
tors localize in clusters on the cell membrane but the 
P i /  07 chimeric LFA-1 and wild-type LFA-1 d o  not 
demonstrates that the f t  cytoplasmic dom ain plays an 
important role in mobilizing LFA-1 into clusters. Oth­
ers have demonstrated that the NPIY motif within the 
Pi cytoplasmic domain is important for localization of 
the integrin into focal contacts (Reszka et a l ,  1992; 
Mauro and Dixon, 1994; O'Toole et a l ,  1995). Interest­
ingly, this motif is absent in the p 2 and P7 cy toplasmic 
domain (Figure 2), which may explain the absence of 
a clustered LFA-1 distribution on the wild-type a-Lp2 
and the chimeric ctLp 2/ f t  transfectants. This finding  
again demonstrates that clustering of LFA-1 in itself is 
essential but not sufficient to stimulate stable LFA-1 /  
ICAM-1 adhesion. Both high-avidity (clustering) and 
high-affinity (active conformation induced by PM A) 
states of LFA-1 cooperated for strong adhesion.
It has been demonstrated that integrins can associate 
with cytoskeletal components (a-actinin and talin), 
particularly through the /3-chain, and thereby regulate 
the cell surface distribution of the integrin (Bum et a l ,
1988; Pavalko and LaRoche, 1993). Deletion of the 
cytoplasmic tail may disconnect the integrin from the 
cytoskeleton and allow lateral movement of the inte­
grin at the cell membrane, explaining the clustered 
distribution of LFA-1 on the aLft/A 7 2 4  transfectants. 
Furthermore, it may well be that clustering of inte­
grins on the cell surface colocalizes important kinases 
essential for proper signal transduction (Miyamoto et 
a l ,  1995). Not only is the intracellular conformation or 
association with regulatory proteins affected by clus­
tering of integrins on the cell surface but also the 
extracellular conformation is altered, as evidenced by 
enhanced LI 6 epitope expression when the p2 cyto­
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plasmic domain was deleted or replaced for the ft 
cytoplasmic domain. This may be attributed to distinct 
interactions with cytoplasmic proteins that affect the 
extracellular conformations of the integrin molecule.
We have demonstrated that the cytoplasmic domain 
of the j3-chain of integrins is responsible for the cell 
surface distribution of the integrin, regulating the ac­
tivation of the integrin and that it plays an essential 
role, either directly or indirectly, in PMA-induced sig­
naling. Furthermore, PMA can activate integrins on 
K562, whereas it failed to activate the lymphocyte- 
specific /32 and ^  integrins in K562, suggesting that 
PMA activates f t  and /37 integrins through lympho- 
cyte-specific elements that are absent in the nonlym- 
phocytic cell line K562.
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